Could 'good' immune cells prevent transplant complications in blood cancer?

NCT ID NCT05088356

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated Apr 29, 2026 · Updated 16 times

Summary

This early-phase trial tests a new approach for people with advanced blood cancers who are getting a stem cell transplant. Instead of using strong drugs to prevent graft-versus-host disease (a common complication where donor cells attack the patient), researchers will give specially prepared donor immune cells (regulatory T-cells) to help control the immune response. The goal is to see if this can reduce side effects and improve survival. About 77 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Stanford University
RECRUITING

Stanford, California, 94304, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACUTE LEUKEMIA ADVANCED HEMATOLOGIC MALIGNANCIES ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) CHRONIC MYELOGENOUS LEUKEMIA MYELODYSPLASTIC SYNDROMES MYELODYSPLASTIC SYNDROMES MYELOPROLIFERATIVE DISORDERS